Research programme: morning akinesia therapeutic - Contera/Solural/Ernst Moritz Arndt UniversityAlternative Names: SOL 707
Latest Information Update: 29 Oct 2015
At a glance
- Originator Contera Pharma; Ernst-Moritz-Arndt-University of Greifswald; Solural Pharma
- Developer Contera Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Paralysis
Most Recent Events
- 17 Feb 2015 Early research in Paralysis (morning akinesia in patients with Parkinson's disease) in Denmark (unspecified route)
- 17 Feb 2015 Early research in Paralysis (morning akinesia in patients with Parkinson's disease) in Germany (unspecified route)